Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492954 | 0.94 | CYP3A4 (0.56) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492961 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492944 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492965 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22577390 | 0.87 | CYP3A4 (0.57) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492952 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492941 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492962 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492946 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22492959 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389463-B2 | Antiviral nucleoside reverse transcriptase inhibitor | SHENZHEN TARGETRX, INC. (CN) | 2022-07-19 | — | — | US | disclosed |
| US-20210093650-A1 | NOVEL ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX, INC. (CN) | 2021-04-01 | — | — | US | disclosed |
| EP-3719027-A1 | NOVEL ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | Shenzhen TargetRx, Inc. (CN) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093650-A1 | NOVEL ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | HPRT1, NUDT1, TYMP | CYP3A4 375/4885CYP2D6 196/4885ADORA2A 2358/4885 |
| US-11389463-B2 | Antiviral nucleoside reverse transcriptase inhibitor | HPRT1, TYMP, NUDT1 | CYP3A4 375/4885CYP2D6 180/4885ADORA2A 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.